Published in Cytotechnology on September 01, 1998
New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc Natl Acad Sci U S A (2003) 1.51
β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. Int J Oncol (2013) 0.94
Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells. Cancer Res (2011) 0.91
Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. Mol Cancer Ther (2008) 0.90
Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy. BMC Gastroenterol (2014) 0.81
A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. Int J Colorectal Dis (2015) 0.79
Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N? BMJ Open (2013) 0.78
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. Clin Genitourin Cancer (2013) 0.78
DNA repair enzymes. Annu Rev Biochem (1988) 5.16
ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne's syndrome and preferential repair of active genes. Cell (1992) 4.80
Proliferating cell nuclear antigen is required for DNA excision repair. Cell (1992) 4.65
Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med (1996) 4.51
Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. Science (1995) 4.48
Second pathway for completion of human DNA base excision-repair: reconstitution with purified proteins and requirement for DNase IV (FEN1). EMBO J (1997) 3.96
Reconstitution of human DNA repair excision nuclease in a highly defined system. J Biol Chem (1995) 3.90
A presumed DNA helicase encoded by ERCC-3 is involved in the human repair disorders xeroderma pigmentosum and Cockayne's syndrome. Cell (1990) 3.48
Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res (1990) 3.38
GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science (1995) 3.34
The base excision repair pathway. Trends Biochem Sci (1995) 3.24
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A (1992) 3.22
Reaction mechanism of human DNA repair excision nuclease. J Biol Chem (1996) 3.20
Specific association between the human DNA repair proteins XPA and ERCC1. Proc Natl Acad Sci U S A (1994) 3.19
Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell (1986) 3.17
Mice with DNA repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities and die before weaning. Nat Genet (1993) 2.87
Mechanisms of DNA excision repair. Science (1994) 2.69
Mismatch repair, genetic stability, and cancer. Science (1994) 2.65
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol (1998) 2.26
DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res (1979) 2.08
Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem (1996) 2.01
Formation of a ternary complex by human XPA, ERCC1, and ERCC4(XPF) excision repair proteins. Proc Natl Acad Sci U S A (1994) 2.00
Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest (1994) 1.97
P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev (1995) 1.92
Where transcription meets repair. Cell (1994) 1.79
Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A (1987) 1.71
Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest (1991) 1.62
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res (1996) 1.60
Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol (1991) 1.49
Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2. Cancer Res (1995) 1.46
ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst (1992) 1.46
Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol (1992) 1.39
The measurement of cisplatin-DNA adduct levels in testicular cancer patients. Carcinogenesis (1988) 1.38
Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest (1986) 1.35
Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro. Proc Natl Acad Sci U S A (1982) 1.33
Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J Biol Chem (1991) 1.32
Genomic characterization of the human DNA excision repair gene ERCC-1. Nucleic Acids Res (1987) 1.31
Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer (1996) 1.24
A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res (1997) 1.20
Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res (1990) 1.19
Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis (1993) 1.18
Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res (1990) 1.17
Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res (1993) 1.15
Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis (1991) 1.08
Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer (1994) 1.03
Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res (1992) 1.03
Formation of covalent complexes between human O6-alkylguanine-DNA alkyltransferase and BCNU-treated defined length synthetic oligodeoxynucleotides. Nucleic Acids Res (1988) 1.02
Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol (1995) 1.01
Partial characterization of the DNA repair protein complex, containing the ERCC1, ERCC4, ERCC11 and XPF correcting activities. Mutat Res (1995) 0.99
Glutathione and drug resistance. Cancer Invest (1996) 0.95
Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol (1993) 0.94
Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Cancer Epidemiol Biomarkers Prev (1993) 0.93
p53 tumor-suppressor gene: clues to molecular carcinogenesis. J Cell Physiol (1997) 0.93
Appropriate partners make good matches. Science (1995) 0.93
Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst Monogr (1993) 0.92
Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. Cancer Res (1996) 0.91
Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA. Carcinogenesis (1990) 0.90
Determinants of cisplatin sensitivity in non-malignant non-drug-selected human T cell lines. Mutat Res (1992) 0.88
Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues. Oncol Rep (2000) 0.88
Expression of excision repair genes in non-malignant bone marrow from cancer patients. Mutat Res (1993) 0.86
A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. Gynecol Oncol (1996) 0.86
Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro. Environ Health Perspect (1992) 0.85
Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification. Cancer Lett (1996) 0.84
Expression of an alternatively spliced ercc1 messenger-RNA species, is related to reduced DNA-repair efficiency in human T-lymphocytes. Oncol Rep (1995) 0.83
Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA. Int J Oncol (1996) 0.83
Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines. Int J Mol Med (1998) 0.82
A preliminary risk-benefit assessment of paclitaxel. Drug Saf (1995) 0.81
Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay? Mutat Res (1987) 0.78
Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy. Cancer Res (1992) 0.78
Comparative analyses of relative ERCC3 and ERCC6 mRNA levels in gliomas and adjacent non-neoplastic brain. Mol Carcinog (1996) 0.77
Effect of cadmium on human ovarian cancer cells with acquired cisplatin resistance. Cancer Lett (1995) 0.76
Re: M. D. Dabholkar et al., Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2. Cancer Res., 55: 1261-1266, 1995. Cancer Res (1995) 0.76
Platinum-DNA adduct in head and neck-cancer patients receiving Cisplatin and Carboplatin chemotherapy. Int J Oncol (1993) 0.76
A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary. Gynecol Oncol (1996) 0.76
Demonstration of a polymorphism in the gene ERCC1 by two DNA sequencing methods. Oncol Rep (2011) 0.76